Background: The purpose of this prospective randomized controlled trial was to determine whether or not intermaxillary fixation in conjunction with dextrose injection prolotherapy was effective in treating hypermobility of the temporomandibular joint. Patients and methods: Twenty patients suffering with TMJ hypermobility were the subjects of this investigation. Each patient was randomly assigned to one of two groups: In Group A, patients received a single injection of 25% dextrose into the back of their joints around the joints. For two weeks, patients in Group B received a combination of 25% dextrose and IMF. At 2 weeks and 1, 3, and 6 months postoperatively, we measured interincisal distance, digital panoramic radiograph, incidence of recurrent dislocation, joint sound, and TMJ pain.Twenty patients suffering with TMJ hypermobility were the subjects of this investigation. Each patient was randomly assigned to one of two groups: In Group A, patients received a single injection of 25% dextrose into the back of their joints around the joints. For two weeks, patients in Group B received a combination of 25% dextrose and IMF. At 2 weeks and 1, 3, and 6 months postoperatively, we measured interincisal distance, digital panoramic radiograph, incidence of recurrent dislocation, joint sound, and TMJ pain. Results: During the follow-up periods, the data showed that both groups experienced a decrease in MMO, a marked improvement in TMJ pain on palpation, tenderness, number of dislocations, and joint sound. Mean MMO values were considerably lower in Group B compared to Group A at the 3- and 6-month follow-ups. Conclusion: Prolotherapy with 25% shows promise for the treatment of symptomatic TMJ hypermobility due to its therapeutic benefits, ease of administration, safety, and absence of major adverse effects. Implementing IMF following the injection of dextrose enhances the outcomes.